Kalaris Therapeutics Inc. (KLRS) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, KLRS scores 31 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillars are cash generation and institutional/insider conviction, both of which sit in the bottom quartile of their 20-point ranges. For a prospective investor, the rating indicates that the reported economics currently do not support the equity on a cash-generation basis, and that positioning signals from institutions and insiders are not supportive. The balance sheet pillar is the least weak component, which means near-term solvency is not the primary concern flagged by the rating; the concern is the absence of cash earnings relative to the company's spending. Any upside case would need to rest on factors outside the rating's current inputs, such as clinical or pipeline developments, which the source data does not detail.

Per the SEC financials, the company reported zero revenue and operating losses across all three periods, with net losses of $-43.4M in FY 2025, $-69.2M in FY 2024, and $-190.4M in FY 2023. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash rose to $98.1M in FY 2025 from $1.6M in FY 2024, while the debt line is listed as N/A in every period.

Per the recent news feed, six items reference KLRS. Simply Wall St and TradingView items are tagged as yellow market-wire coverage describing general market action and institutional positioning. A Benzinga item on three beaten-down biotech stocks backed by a specialist investor is tagged as a green catalyst. Two items headlined as Q2 2026 earnings, both attributed to a source at a dars.gov.et domain, are tagged as red risk-watch items; one reports a narrower-than-expected loss of $0.48 per share while shares slipped 4.5%. A Traders Union price-prediction item is tagged yellow. Per the Butterfly Supply-Chain Graph, a LIQUIDITY_TAILWIND proprietary signal is bullish with a severity score of 90 and a macro tailwind score of 91/100. It cites a 2.86x Net Liquidity beta and an r of -0.18, with the True Net Liquidity Index at $5,745.73B and a 4-week rate of change of -0.64%. Per the same graph, the signal is a macro-liquidity read and does not describe a company-specific fundamental event.

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE and there are no butterfly links, so upstream and downstream dependencies are not available in source data. The only sector-level linkage in the source is the liquidity signal, which assigns KLRS a 2.86x sensitivity to Net Liquidity changes. Investors should watch for a reversal in the liquidity backdrop, since the signal's bullish reading depends on current Fed, Treasury General Account, and Reverse Repo levels. The sensitivity is high but the correlation is weak at r = -0.18, so the signal explains only a limited share of return variation. Sector-level correlations and 2nd-order bottlenecks beyond this are not available in source data.

• What are KLRS's products, pipeline stage, and revenue pathway, given zero reported revenue across three years?
• What is the basis for the reported FY 2025 cash balance of $98.1M, and what is the company's runway at current FCF burn?
• What is the debt position, since debt is listed as N/A in every period despite a Debt/Equity of 0.5?
• What drove the reported Q2 2026 loss per share of $0.48 and the narrowing versus expectations?
• Do the institutional and insider positions referenced by the RQD rating have identifiable holders or transaction dates in the source?